Current Report Filing (8-k)
April 10 2020 - 9:29AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): April 10, 2020
ENDONOVO
THERAPEUTICS, INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
|
000-55453
|
|
45-2552528
|
|
(State
or other jurisdiction of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS Employer
Identification No.)
|
6320
Canoga Avenue, 15th Floor
Woodland
Hills, CA 91367
(Address
of principal executive office)(Zip Code)
Registrant’s
telephone number, including area code: (800) 489-4774
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
|
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
|
Common Stock, par
value $0.0001 per share
|
|
ENDV
|
|
OTCQB
|
Item
8.01 Other Events.
On
April 10, 2020, the Registrant board of directors determined that, in light of the circumstances and uncertainty surrounding the
effects of the COVID-19 pandemic on the business, consultants and service providers, that it will delay the filing of its annual
report on Form 10-K for the year ended December 31, 2019 (the “Annual Report”) by up to 45 days in accordance with
the SEC’s March 4, 2020 Order (Release No. 34-88318) (the “Order”), which allows for the delay of certain filings
required under the Securities and Exchange Act of 1934, as amended. The Registrant’s operations and business have experienced
disruption due to the unprecedented conditions surrounding the COVID-19 pandemic spreading throughout the United States and the
world and thus the Registrant’s business operations have been disrupted and it is unable to timely prepare and review the
Registrant’s financial statements for the 2019 fiscal year. As such, the Registrant will be making use of the 45-day grace
period provided by the SEC’s Order to delay filing of its Annual Report. The Registrant plans to file its Annual Report
by no later than May 14, 2020, 45 days after the original due date of its Annual Report. The Registrant is not able to predict
with certainty the impact of the COVID-19 pandemic on its operations and results.
Item
9.01 Financial Statements and Exhibits.
None
None
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Dated:
April 10, 2020
|
|
ENDONOVO
THERAPEUTICS, INC.
|
|
|
|
|
|
|
By:
|
/s/
Alan Collier
|
|
|
|
Alan
Collier
|
|
|
|
Chief
Executive Officer
|
Endonovo Therapeutics (PK) (USOTC:ENDV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Endonovo Therapeutics (PK) (USOTC:ENDV)
Historical Stock Chart
From Apr 2023 to Apr 2024
